CompletedPhase 1/2

Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Japan27 participantsStarted 2018-07-24

Plain-language summary

To investigate the safety and efficacy of PRI-724 against HCV or HBV liver cirrhosis.

Who can participate

Age range

20 Years – 74 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients with serum HCV-RNA positive or HCV antibody positive
. Patients with serum HBV-DNA positive or HBs antigen positive
. confirmed liver cirrhosis by liver biopsy performed in the screening period patients who received diagnosis
. Patients who have not reached SVR \* with DAA therapy
. Patients who are difficult to implement DAA therapy
. Patients who have been over 24 weeks after achieving SVR \* with DAA therapy In case of HBV cirrhosis;
. Patients who have been at least 24 weeks since the start of administration of Nucleotide analogue \* SVR is SVR 12 (sustained virological response at 12 weeks after the end of administration).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Serious side effect expression rate

Timeframe: 12 weeks after administration

liver tissue fibrosis area ratio by liver biopsy

Timeframe: 12 weeks after administration

Trial details

NCT IDNCT03620474

SponsorKiminori Kimura, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-07-13

View on ClinicalTrials.gov More Hepatitis C trials